Partner Frank Murray was quoted in a Bloomberg article, “Amazon’s $10 Billion Pentagon Challenge: Proving Trump Meddled,” about Amazon’s uphill battle to overturn a Pentagon decision to award a $10 billion cloud-computing contract to archrival Microsoft.
To help make its case, Murray said, Amazon could examine whether there were any differences between how the companies’ bids were evaluated by lower level technical staff and top Pentagon officials. If top officials overrode the recommendation of their technical staff, that could be a significant piece of evidence for Amazon. “The nuts and bolts of the case are going to be: how were the proposals evaluated? And were they reasonable?” he said.
(Subscription required)
To help make its case, Murray said, Amazon could examine whether there were any differences between how the companies’ bids were evaluated by lower level technical staff and top Pentagon officials. If top officials overrode the recommendation of their technical staff, that could be a significant piece of evidence for Amazon. “The nuts and bolts of the case are going to be: how were the proposals evaluated? And were they reasonable?” he said.
(Subscription required)
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”